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Connecticut
Genetic engineering is the process of modifying an organism’s genetic composition by
adding foreign genes to produce desired traits or evaluate function. Dr. Jon W. Gordon and
Sterling Professor Emeritus at Yale Dr. Frank H. Ruddle were pioneers in mammalian gene
transfer research. Their research resulted in production of the first transgenic animals, which
contained foreign DNA that was passed on to offspring. Transgenic mice have revolution-
ized biology, medicine, and biotechnology in the 21st century. in brief, this review revisits
their creation of transgenic mice and discusses a few evolving applications of their trans-
genic technology used in biomedical research.
INTRODUCTION
After service in the U.S. Air Force fol-
lowing World War II, Dr. Frank H. Ruddle
completed his undergraduate education at
Wayne State University in Detroit, Michi-
gan, in 1953 and two years later received a
master’s degree in science from the same
institution. In 1960, Dr. Ruddle earned his
doctorate in biology from the University of
California at Berkeley, where he studied
chromosome patterns in established cell
cultures. Dr. Morgan Harris, a prominent
cell biologist, mentored Dr. Ruddle during
his  time  at  Berkeley.  Immediately  after
graduate school, Dr. Ruddle went to the
University of Glasgow to pursue his inter-
ests in somatic recombination. As a post-
doctoral associate, he worked with Drs.
John Paul and Guido Pontecorvo, leaders
in modern genetics at the time. Dr. Ruddle
was greatly interested in Pontecorvo’s work
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After  brief  postdoctoral  training  at
Glasgow, Dr. Ruddle became an assistant
professor in the Yale Biology Department in
1961. Once at Yale, Dr. Ruddle continued to
pursue his interests in somatic cell genetics.
Transfer of genetic material from a human
cell to another type of cell in culture was
state of the art for somatic cell genetics in
the 1960s, since this “somatic cell hybrid”
system allowed recombination and segrega-
tion of genes. Development of techniques to
stain chromosomes made it possible to dis-
tinguish between mouse and human chro-
mosomes. In a mouse-human mixture of
cells, many human chromosomes were lost
from the hybrid cell lines. Furthermore, with
the absence or presence of certain chromo-
somes, one could assign genes to particular
chromosomes, as determined by the corre-
lation of known gene products, such as en-
zymes. Once gene location was established,
genetic linkage could be determined by an-
alyzing other proteins to determine if they
were also lost or gained. This system simu-
lated  genetic  segregation  in  meiosis,
whereby genes that are physically close to
each other on the same chromosome usually
do not separate. These predictions could be
confirmed with in situ hybridization to probe
specific genes of metaphase chromosomes.
Dr. Ruddle’s laboratory adopted this somatic
cell hybrid approach to determine the phys-
ical  location  of  genes  on  chromosomes,
which proved a difficult task at the time. Dr.
Ruddle’s lab made valuable contributions to
the exploration of the genome, including
mapping of the human interferon, pro-colla-
gen, and ʲ-globin genes [1-3]. With enthusi-
asm for the growing field of gene mapping,
Dr. Ruddle initiated a Human Gene Map-
ping Workshop, which began in 1973. Lo-
cated  at  Yale,  this  workshop  offered
hundreds of geneticists the opportunity to
discuss recent literature in order to assign
particular genes to precise locations on chro-
mosomes. Almost 100 genes were cited in
the report of the first Human Gene Mapping
Workshop, and this number grew to more
than 2,000 entries by the Tenth Human Gene
Mapping Workshop in 1989 [4]. Further-
more, Dr. Ruddle created a database at Yale,
called the Human Gene Map (HGM†) li-
brary, which was the main source of human
gene mapping information for those in the
gene mapping community [5]. In many as-
pects,  Dr.  Ruddle  was  a  pioneer  of  the
Human Genome Project before its inception
in 1989.
ApplICATION OF SOMATIC CEll
GENETICS TO pRODUCE 
TRANSGENIC MICE
In the late 1970s, Dr. Ruddle began the
first of two appointments as chairman of the
Biology Department, now Molecular, Cel-
lular, and Developmental Biology, at Yale
University. He also held a joint appointment
in Yale School of Medicine’s new Depart-
ment of Human Genetics. As his profes-
sional  duties  expanded,  his  laboratory
interests did, too, to include applications of
somatic cell genetic techniques to mam-
malian gene transfer, with the hopes of cre-
ating a mouse model to study developmental
gene regulation and human disease. Previ-
ously, Rudolf Jaenisch and Beatrice Mintz
from Fox Chase Cancer Center in Philadel-
phia showed that when mouse embryos were
infected with Simian virus (SV40), this viral
DNA could be integrated into the germ line
[6,7]. However, it was unclear whether spe-
cific genes, previously manipulated in vitro,
could be stably introduced into mice if one
used a similar approach as Jaenisch and
Mintz. Also in the late 1970s, Dr. Jon W.
Gordon had completed his PhD at Yale Uni-
versity. In Dr. Clement L. Markert’s labora-
tory, Dr. Gordon’s graduate training focused
on mouse developmental biology as he used
mouse embryos to study how single genes
can affect determination of cell phenotype.
Dr. Gordon decided to stay at Yale as a post-
doctoral fellow in Dr. Ruddle’s lab to pur-
sue a novel project. In collaboration, Dr.
Gordon and Dr. Ruddle produced the first
“transgenic”  animal.  They  generated  a
mouse  in  which  specified  foreign  genes
were inserted into its genome and transmit-
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tance. Furthermore, injection of this cloned
DNA into freshly fertilized mice embryos
reduced the occurrence of mosaicism, or so-
matic cells with more than one genotype, as
seen in previous attempts [6,8,9]. This work
was published in seminal papers in Pro-
ceedings of the National Academy of Sci-
ences  and Science  in  1980  and  1981,
respectively [10,11]. 
To summarize their work, several re-
combinant plasmids were created and modi-
fied  for  the  purpose  of  tracking  specific
genes after introduction into mammalian em-
bryos. The first plasmid, named pST6, was a
derivative of pBR322, a widely used bacter-
ial plasmid for cloning at the time. The au-
thors inserted a portion of the SV40 virus and
the herpes simplex virus thymidine kinase
(TK) gene. These sequences would allow for
DNA replication and confirmation of gene
transfer, respectively. For negative controls,
they created variations of the pST6 plasmid,
which included reversal of the SV40 se-
quence and formation of dimerized pST6
plasmids.  These  were  termed  pST9  and
pST12, respectively. A second type of plas-
mid, pRH 1.3Mm 1, also was derived from
the pBR322 plasmid. It contained a random
and interspersed sequence. If DNA integra-
tion was mediated by homologous recombi-
nation,  this  sequence  would  increase
integration frequency, as it was shown that
repetitive sequences caused a high frequency
of recombination and formation of recombi-
nant genomes in yeast [12]. Next, Dr. Ruddle
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Figure 1 (modified from [38]). Generation of the first transgenic mouse. To create
transgenic animals (mice shown here), male and female mice were mated. The single-
celled embryo was obtained from the pregnant female. DNA was microinjected into the
pronucleus of a fertilized ovum. once injected, surviving embryos were re-implanted into
the oviduct of pseudopregnant female recipients. These females gave birth about 3 weeks
after implantation. Transgene integration from litters was assessed by tissue analysis. This
DNA injection into the pronucleus was the first and still most commonly used technique to
make transgenic animals. and Dr. Gordon aimed to inject their purified
DNA into single-celled embryos to ensure
passage to all daughter cells. However, this
would be technically challenging because of
the small size of the embryos. To solve this
problem, very fine microneedles were cre-
ated from capillary tubes. In addition, hold-
ing pipettes were constructed from capillary
tubes in order to stabilize the embryo. By
capillary action, DNA was collected into the
microneedle for injection. Their recombinant
plasmids were then “microinjected” into sin-
gle-celled mouse embryos at the pronuclear
stage of development. Surviving eggs were
implanted into psuedopregnant females. Off-
spring were born 3 weeks later, and they
were subjected to DNA analysis by Southern
blot (Figure 1). Of the 78 mice injected with
the original pST6 plasmid, only two of 78
animals were positive for transformation, as
determined by Southern blot hybridization to
the pST6 probe. Furthermore, only one ani-
mal contained the DNA in integrated form as
probed with TK, albeit the gene was modi-
fied. The other animal appeared to keep por-
tions of the plasmid DNA without integration
of the TK gene. Animals that were unin-
jected, or injected with the other plasmids
mentioned, were not positive for DNA trans-
formation. Despite a low success rate, this
study served as proof of principle that cloned
DNA  could  be  directly  inserted  into  the
mouse  genome.  Furthermore,  incomplete
inter-species sequence homology between
donor and recipient was not an obstacle to
prevent transformation, as human TK was
expressed in mice, suggesting that it might
be possible to transfer any gene between dis-
tinct species. Lastly, failure to see any trans-
formed mice with the pRH 1.3Mm 1 plasmid
suggested that this phenomenon appeared to
be predominantly random and not mediated
by  homologous  recombination.  One  year
later, Dr. Ruddle and Dr. Gordon reported in
Sciencethat these transgenic mice could pass
the inserted genes to their offspring [11].
Hence, these sequences had become a stable
part of the genome. 
After the initial finding, several groups
rapidly published similar findings that also
showed integration and germ line transmis-
sion of foreign DNA. While the TK gene
that Dr. Gordon and Dr. Ruddle injected did
not induce an obvious phenotypic change,
studies were published soon after that phe-
notypically demonstrated overexpression of
exogenous genes. Proof of principle was
dramatically manifested in mice transgenic
for the rat and human growth hormone gene,
which stimulated significant growth in the
transgenic mice compared to their litter-
mates, described by Palmiter and Brinster
[13,14]. Taken together, these exciting find-
ings set the stage for a revolution in the use
of genetically modified organisms as a stan-
dard investigative tool in research.
ADvANCES IN TRANSGENIC 
TEChNOlOGy
Compared to the 2 percent success rate
of the original studies by Dr. Gordon and Dr.
Ruddle, rapid refinement in the methodol-
ogy led to 15 percent of offspring carrying
the target gene [15,16], which today remains
virtually unchanged, but depends on the size
of DNA injected, species, and other vari-
ables. In addition, new ways to make trans-
genics were subsequently discovered and
include embryonic stem cell transfer into
embryos and recombinant virus infection of
embryos [17,18]. Today, transgenic overex-
pression and targeted deletion are the two
most common approaches to genetic manip-
ulation. Gene null (knockout and knockin)
mice  are  expansions  of  the  fundamental
principle of transgenesis. Similar to trans-
genic mice, knockout mice also are created
using cloned DNA in embryonic stem cells
(which in this case has similarities to the
gene of interest) that allows for homologous
DNA recombination to achieve site-specific
disruption. 
In conventional transgenic mice, the
gene is introduced in the first cell of the em-
bryo and is passed to all cells of the adult an-
imal,  presumably  allowing  constitutive
expression of the protein. However, innova-
tive approaches have led to the ability to
make a transgenic mouse capable of ex-
pressing  protein  in  a  cell/organ  specific
manner by using tissue specific promoters.
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control of the K14 or Vav promoter, which
are  specific  for  keratinocytes  and
hematopoietic cells, respectively [19,20].
Therefore, genes of interest will be uniquely
overexpressed in the desired cell type. In ad-
dition to spatial specificity, temporal speci-
ficity  is  important  since  genes  can  play
many roles dependant on the developmental
stage of an organism. To overcome this, sys-
tems of inducible gene expression systems
have been designed in which the expression
of the desired gene is placed under the con-
trol of a cis acting element, which will re-
spond  to  specific  molecules  that  are
introduced into the system. Examples in-
clude  steroid  hormone-based,  antibiotic,
heavy metal ion, and heat shock inducible
systems [21]. In addition to overexpressing
foreign genes into organisms, transgenes
also have the potential to silence desired
genes  by  introduction  of  DNA  encoding
short hairpin RNAs, which lead to cleavage
of specific messenger of RNA. Similarly,
transgenic mice can be used to create a con-
ditional knockout mouse. Mice transgenic
for Cre, a DNA recombinase, can be crossed
with transgenic mice in which loxP sites
have been introduced that flank a gene of in-
terest (DNA is then said to be “floxed”).
Since loxP sites contain a binding region for
Cre, the gene of interest will be deleted as a
result of the Cre-lox recombination. As dis-
cussed earlier, the inducible systems of gene
expression can be used to turn on Cre, which
then lead to deletion of the floxed gene.
These mice are known as conditional knock-
out mice. This system is very useful when
normal gene disruption results in embryonic
lethality. Importantly, these mice also can be
under spatial control, again by using using a
tissue specific promoter to overexpress Cre.
In addition, the Cre-lox system can be used
to induce genes in spatio-temporal fashion,
by mechanisms not described here.
Dr. Ruddle’s lab has continued to use
transgenic technology while focusing on the
Hox family genes and their roles in devel-
opment and evolution. His lab has realized
that variations in regulatory regions of these
developmental control genes can influence
their gene transcription and may contribute
toward evolution [22]. Similarly, it was re-
alized that production of some transgenic
mice fail because the relatively small DNA
construct injected does not contain critical
regulatory regions of the gene, such as a sec-
tion of the promoter or enhancers that may
be  necessary  for  transgene  expression.
Therefore, expression of transgene is sub-
jected to being silenced by surrounding host
sequences. This phenomena is known as po-
sitional  effect  [23].  Such  obstacles  have
been overcome through bacterial artificial
chromosomes (BACS) and yeast artificial
chromosomes (YACS) [24,25]. These DNA
“vehicles” allow transfer of large fragments
of  cloned  genomic  DNA,  which  contain
necessary regulatory elements for expres-
sion. Due to the large size of YACS, the lo-
cation of the desired gene will not interfere
with expression. However, YACS lead to
high  rates  of  chimerism,  difficulty  with
DNA isolation and cloning, and insert insta-
bility [26]. BACS have emerged as a solu-
tion to this problem due to their relative ease
of handling and insert stability. However, the
maximum insert size that BACS can ac-
commodate is much smaller than that of
YACS. With further contribution to trans-
genic technology, Dr. Ruddle’s lab has engi-
neered a system that uses a yeast-bacteria
shuttle vector (pClasper), which combines
the two strengths of the systems without the
disadvantages [27]. Using this vector, large
regions from a YAC or BAC can be cloned
and stably maintained in both yeast and bac-
teria.  Further  DNA  manipulation  can  be
made relatively easily in yeast and finally
transferred to bacteria for simple isolation.
A recent example of this technology has
been used to isolate large stretches of DNA
from a BAC clone that includes upstream
and downstream noncoding sequences of the
Chst4 (Hec-6st) gene, which is specific for
high endothelial venules (HEVs). Addition-
ally, reporter genes, ʲ-galactosidase or green
fluorescent protein (GFP), were inserted into
an exon of the Chst4 gene, allowing simul-
taneous expression of the endogenous gene
and transgene and real time visualization of
HEVs in vivo [28,29]. 
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TEChNOlOGy
As more information is discovered con-
cerning  the  genetic  etiology  of  diseases,
transgenic and null mice have been devel-
oped in a concerted fashion to allow re-
searchers  an  opportunity  to  study  and
understand the function of gene products.
One such example is an animal model used
to study hepatitis B virus (HBV) infection,
developed shortly after Dr. Gordon and Dr.
Ruddle’s transgenic mouse [30]. To mimic
the situation found in HBV carriers, mice
transgenic for a hepatitis B surface antigen
(HBsAg)  were  produced.  Similar  to  the
pathology in humans, increased expression
of this antigen leads to severe liver cell dam-
age and an inflammatory response. Many
details on the mechanism of HBV virus in-
fection and pathological consequences have
been gained through this model. Likewise,
many other other transgenic mice created
have  become  valuable  models  to  study
mechanistic aspects of human disease.
In addition to using animal models for
mechanistic studies, the pioneering trans-
genic technology created by Dr. Gordon and
Dr. Ruddle has applications in medicine. For
example, donor animals suitable for xeno-
transplantation, such as pigs, have emerged
as a solution to the shortage of allogeneic or-
gans [31]. To prevent human rejection of pig
grafts, pigs transgenic for human leukocyte
antigen and other corrections for immuno-
logical incompatibilities have been gener-
ated in order to attenuate the risk of acute
rejection [32]. Transgenic animals also are
used for large-scale production of therapeu-
tic proteins, such as blood clotting factors
(i.e., Factor VIII), which is otherwise de-
pendant on isolation from scarce sources of
human  plasma  [33].  In  addition,  human
monoclonal antibodies used to treat cancer
and autoimmune diseases are produced in
transgenic  mice. Antibodies  produced  in
transgenic animals are typically less expen-
sive and provide a greater yield than mam-
malian cell culture. Lastly, the idea of gene
therapy seeks to use genetic engineering to
benefit humans by replacing defective genes
with normal copies. A classic example oc-
curs in sickle cell anemia, in which a point
mutation in the gene for beta globin, a pro-
tein  component  of  hemoglobin,  leads  to
sickle cell pathology. Replacing this mutated
gene with a normal beta globin gene is a
promising strategy, although this approach
has been limited by technical challenges
such as the immunogenicity of viral vectors
used to deliver the genes and delivery to the
appropriate cell type.
In agriculture, crops traditionally have
been altered by crossing plants with indi-
vidual favorable traits to produce new vari-
ety that contain both traits. This method
relies on homozygous recombination that by
chance may generate genetic diversity. Al-
ternatively, transgenic plants provide an ef-
ficient solution to select desired traits. This
can, in turn, reduce crop losses and improve
plant growth, ultimately providing a stable
supply of food for the increasing global pop-
ulation. For example, plants transgenic for
toxin  genes  from  the  bacteria,  Bacillus
thuringiensis, are insect resistant [34]. Fur-
thermore, genes that are important for her-
bicide resistance also can be introduced into
plants [34]. Meanwhile, depletion of fossil
fuel reserves raises interest in the use of re-
newable energy sources such as biofuels.
Many biofuels are made from plant mass.
Similar to plants for nutritional consumption
by humans, transgenic plants engineered for
biofuel  production  have  important  traits
such as pest and herbicide resistance, resist-
ance to disease, and other modifications that
will allow it to thrive in sub-optimal condi-
tions.
CONClUDING REMARkS
Prior to the transgenic mouse, knowl-
edge of gene function in mice only came
about through forward genetics in exten-
sively inbred mice, which used radiation or
a different mutagen to affect the genotype,
with the hopes of observing a resulting phe-
notype.  As  mentioned  earlier,  favorable
traits in animals and plants were selected by
outbreeding. Molecular biology techniques
and genetically modified organisms have, in
parallel, allowed rapid acceleration of sci-
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demonstration  of  foreign  gene  transfer
began a revolution in the use of animal mod-
els  for  biomedical  research.  Importantly,
their contributions did not end there. Dr. Jon
Gordon has mentored the next generation of
scientists  since  he  joined  the  faculty  of
Mount Sinai School of Medicine in 1982. As
an expert in recombinant DNA technology,
he has shared his insights in the form of
books, reviews, and primary research arti-
cles [35,36]. As mentioned earlier, Dr. Rud-
dle  has  continued  to  improve  transgenic
technology, while applying it to study fun-
damental biological questions. Additionally,
he has helped advance the field of genomics,
a word that he helped coin [37]. As a Ster-
ling Professor Emeritus at Yale, he contin-
ues to publish primary research articles and
is active in the scientific community. He has
received many well-deserved awards, in-
cluding induction into the National Acad-
emy of Science.
In summary, the pioneering work of Dr.
Gordon and Dr. Ruddle has opened new av-
enues for research. Transgenic technology
continues to hold great promise for the fu-
ture but must be met with sound ethical rea-
soning  by  scientists,  the  biotechnology
industry, government and the public.
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